We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Anbio Biotechnology Presents Point-Of-Care IVD Solutions

By LabMedica International staff writers
Posted on 08 Feb 2024
Print article
Image: Top-level POCT solutions on display at Medlab Middle East 2024 (Photo courtesy of Anbio)
Image: Top-level POCT solutions on display at Medlab Middle East 2024 (Photo courtesy of Anbio)

Anbio Biotechnology (Frankfurt, Germany) is demonstrating its FIA, CLIA, LAMP, and dry chemistry analyzers, along with other easy-to-use diagnostic solutions, at Medlab Middle East 2024.

During the trade show, Anbio is showcasing its fluorescence immunoassay (FIA) solutions which include four types of analyzers, from portable handheld to bench-top sizes, as well as a wide range of assays. 78 available assays enable the detection of a variety of analytes, including hormones, cancer markers, cardiac markers, drugs of abuse, inflammation, and infectious diseases. Also on display is Anbio’s ADL i1910 chemiluminescence immunoassay analyzer which is designed to transform the landscape of clinical diagnostics. With an impressive range of 50 CE-marked assays, this fully automated, high throughput, compact CLIA analyzer supports both qualitative and quantitative testing of analytes.

At Medlab Middle East 2024, Anbio is presenting the SHA-100 small-sized, portable, and easy-to-use dry-chemistry analyzer that supports real-time testing and real-time printing of quantitative detection results for 18 test items. Anbio is also demonstrating its LAMP Solution, a diagnostic technique to amplify and detect specific DNA or RNA sequences that is used for various applications, including detecting infectious diseases, genetic disorders, and foodborne pathogens. Anbio’s LAMP solution offers miniaturized analyzers, which are extremely easy to use. The egg-shaped LAMP device is a one-button control capable of delivering fast, sensitive, and specific results for various infectious diseases. It is suitable for over-the-counter (OTC) and point-of-care (POC) diagnostics.

For the first time, Anbio is showcasing the ABO & Rhd Blood Grouping Kit, a qualitative detection test kit for the ABO and D antigen of the Rhd blood group system on human red blood cells in whole blood or 10% red cell suspensions in physiological saline. The ABO & Rhd Blood Grouping Kit is based on the principle of antigen-antibody dot immune filtration assay to provide convenience and accuracy in testing blood types for clinical use and emergencies. It can acquire accurate results from fresh fingertip blood in as little as one minute, with a storage time of 24 months, and does not require special refrigeration or cold-chain transportation. It can quickly display blood type information through paper strip reactions, representing a modern approach to blood type testing.

"Anbio is consistently dedicated to developing easy-to-access and reliable diagnostic test kits for improving user experience in various application scenarios," said Michael Lau, CEO of Anbio Biotechnology. "Anbio's ABO & Rhd Blood Grouping Kit provides a simple way for blood type testing with low requirements for user environment, storage, and transportation while ensuring the accuracy of the results. The target market of this product will be mainly focusing on the Middle East, Asia, and Africa regions. We will continue to invest in user-centric, affordable, and reliable Point-of-Care Testing solutions and bring them to the world."

Related Links:
Anbio Biotechnology

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
HSV-1 Test
Herpes Simplex Virus 1 Test
New
PAPP-A Test
PAPP-A Mass Units AccuBind ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.